AstraZeneca and MedImmune are committed to supporting quality independent education that:

  • Meet an educational need by providing information designed to assist health care professionals in their efforts to enhance patient care
  • Further the understanding of emerging therapies based on a documented unmet need
  • Incorporate evidence-based medicine in the program objectives and methodology
  • Assist health care professionals in carrying out diagnosis and treatment strategies more effectively and efficiently
  • Support the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options
  • Address performance and quality improvement

We focus our support where there is the greatest need in areas that overlap with our areas of interest.

We have incorporated Call for Grant Applications into our process. Please check available Call for Grants below.

Available funding for areas of educational interest

No funding available - check back periodically

Areas of Educational Interest Available Funding Call for Grants
Acute Coronary Syndrome (only accepting submissions < $50,000)
Heart Failure (HF)
Type 1 Diabetes (2019 start dates)
Type 2 Diabetes CGA Endocrinology Type 2 Diabetes 1802 CGA Endocrinolgoy Type 2 Diabetes 1803 CGA T2D 1802 CGA T2D 1803
Research & Development Support
Chronic Kidney Disease (CKD) (2019 start dates)
Hyperkalemia (2019 start dates)
Opioid-Induced Constipation
Advanced Breast Cancer
  • BRCA
  • Non-BRCA
  • DNA Damage Response
  • PARP inhibition
  • Metastatic HR+
Ovarian Cancer
  • BRCA
  • Non-BRCA
  • PARP inhibition
  • DNA Damage Response
  • CLL (Chronic Lymphocytic Leukemia)
  • MCL (Mantle Cell Lymphoma)
  • HCL (Hairy Cell Leukemia)
  • WM (Waldenstrom Macroglobulinemia)
  • imAE Management
  • Non-Metastatic NSCLC
Non Small Cell Lung Cancer
  • EGFR T790m+ NSCLC
Pancreatic Cancer
  • BRCA
  • DNA Damage Response
  • PARP Inhibition
Prostate Cancer (mCRPC)
  • DNA Damage Response
  • Homologus Recombination Repair
  • PARP inhibition
COPD CGA Respiratory COPD 1801 General CGA COPD 1801
Severe Asthma (2019 start dates)
Systemic Lupus Erythematosus
Scientific or educational activities designed to educate research scientists, principal researchers, drug development professionals, academics, pre-doctoral students, doctoral students and fellows. These programs must be educational and non-promotional in nature and planned, designed and implemented in accordance with the U.S. Food and Drug Administration's Guidance on Industry-Supported Scientific and Educational Activities